Skip to content
DraconiticResearch
Search Sources API
197,688 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Effect of the rs12249854 Polymorphism in the HECTD2 Gene and Selected Clinical Variables on the Response to Intradetrusor Injection of Botulinum Neurotoxin Type A in Female Patients with Overactive Bladder: A Single-Center Prospective Study

  • Sylwester Michał Ciećwież1
  • Klaudyna Lewandowska2
  • Agnieszka Boroń2
  • Dariusz Kotlęga3
  • Jacek Kociszewski4
  • Andrzej Ciechanowicz2
4 affiliations
  1. 1Department of Perinatology, Obstetrics and Gynecology, Pomeranian Medical University, 70-204 Szczecin, Poland
  2. 2Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, 70-204 Szczecin, Poland
  3. 3Department of Pharmacology and Toxicology, University of Zielona Góra, 65-417 Zielona Góra, Poland
  4. 4Department of Gynecology, Evangelisches Krankenhaus Hagen, 58135 Hagen, Germany
Open at sourceDOICite

Abstract

The HECTD2:rs12249854 polymorphism may be associated with a weaker response to an intradetrusor injection of botulinum neurotoxin type A (BoNT/A) in patients with overactive bladder (OAB). This prospective study analyzed the link between the HECTD2:rs12249854 polymorphism and the response to BoNT/A treatment in 156 OAB patients, based on changes in urodynamic parameters and ICIQ-OAB and ICIQ-LUTS-QoL scores six months after the injection. BoNT/A treatment contributed to improvements in all parameters except the average flow rate. Wild-type homozygotes (TT, n = 137) differed from TA heterozygotes (n = 19) solely in terms of pretreatment ICIQ-OAB Part A and ICIQ-LUTS-QoL Part A scores, both of which were higher in the heterozygotes. Thus, the HECTD2:rs12249854 polymorphism does not appear to be associated with the response to BoNT/A treatment. Patients with neurogenic OAB (n = 60) had a higher pretreatment detrusor pressure at maximum flow than those with idiopathic OAB (n = 96), but this difference was no longer observed after BoNT/A treatment. Good responders to the BoNT/A injection (defined as at least 50% decrease in the ICIQ-LUTS-QoL Part A score, n = 50) had a higher body mass index and parity and a lower pretreatment maximum flow rate than poor responders (n = 106). Before formulating any definitive conclusions, the results of this exploratory study should be verified in an adequately powered multicenter cohort.

Related

  1. Results from the VANISH study: A prospective multicenter study validating a single-nucleotide polymorphism-based noninvasive prenatal test to assess aneuploidy risk in surviving twins of vanishing twin pregnancies.
    Lorraine Dugoff, Sunni L Mumford, Meredith L Rochon +27
    Pregnancy (Hoboken, N.J.)Peer-reviewedCC BY-NC-NDFull textObstetrics, gynaecology & paediatricsEurope PMC
  2. Component-Level Cost and Variability Drivers of Intradetrusor OnabotulinumtoxinA Injections Across Office and Operating Room Settings
    Saawan D. Patel, Evan Rosario, Robert Stetson +1
    Urology PracticePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Bulging of the Masseter Muscle Following Botulinum Neurotoxin Type A Injection
    Lukas Naef, Epameinondas Gousopoulos, Florian Alexander Huber +1
    Plastic and reconstructive surgery. Global openPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  4. Process-dependent Analytical Differences Among Commercial Botulinum Neurotoxin Type A Formulations
    Hyunjung Choi, Se Na Kim, Chang Ki Lee +4
    Plastic and reconstructive surgery. Global openPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  5. Comparative Safety of Overactive Bladder Treatments—Unexpected Results in Context
    Sudeep S. Gill
    JAMA Network OpenPeer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{ciecwiez2026effect,
  title = {{Effect of the rs12249854 Polymorphism in the HECTD2 Gene and Selected Clinical Variables on the Response to Intradetrusor Injection of Botulinum Neurotoxin Type A in Female Patients with Overactive Bladder: A Single-Center Prospective Study}},
  author = {Sylwester Michał Ciećwież and Klaudyna Lewandowska and Agnieszka Boroń and Dariusz Kotlęga and Jacek Kociszewski and Andrzej Ciechanowicz},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = oct,
  doi = {10.3390/ijms27219571},
  url = {https://www.mdpi.com/1422-0067/27/21/9571},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Effect of the rs12249854 Polymorphism in the HECTD2 Gene and Selected Clinical Variables on the Response to Intradetrusor Injection of Botulinum Neurotoxin Type A in Female Patients with Overactive Bladder: A Single-Center Prospective Study
AU  - Sylwester Michał Ciećwież
AU  - Klaudyna Lewandowska
AU  - Agnieszka Boroń
AU  - Dariusz Kotlęga
AU  - Jacek Kociszewski
AU  - Andrzej Ciechanowicz
PY  - 2026
DA  - 2026/10/26
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms27219571
UR  - https://www.mdpi.com/1422-0067/27/21/9571
AB  - The HECTD2:rs12249854 polymorphism may be associated with a weaker response to an intradetrusor injection of botulinum neurotoxin type A (BoNT/A) in patients with overactive bladder (OAB). This prospective study analyzed the link between the HECTD2:rs12249854 polymorphism and the response to BoNT/A treatment in 156 OAB patients, based on changes in urodynamic parameters and ICIQ-OAB and ICIQ-LUTS-QoL scores six months after the injection. BoNT/A treatment contributed to improvements in all parameters except the average flow rate. Wild-type homozygotes (TT, n = 137) differed from TA heterozygotes (n = 19) solely in terms of pretreatment ICIQ-OAB Part A and ICIQ-LUTS-QoL Part A scores, both of which were higher in the heterozygotes. Thus, the HECTD2:rs12249854 polymorphism does not appear to be associated with the response to BoNT/A treatment. Patients with neurogenic OAB (n = 60) had a higher pretreatment detrusor pressure at maximum flow than those with idiopathic OAB (n = 96), but this difference was no longer observed after BoNT/A treatment. Good responders to the BoNT/A injection (defined as at least 50% decrease in the ICIQ-LUTS-QoL Part A score, n = 50) had a higher body mass index and parity and a lower pretreatment maximum flow rate than poor responders (n = 106). Before formulating any definitive conclusions, the results of this exploratory study should be verified in an adequately powered multicenter cohort.
SN  - 1422-0067
ER  -